Literature DB >> 773533

Relationship between activity and amino sugar stereochemistry of daunorubicin and adriamycin derivatives.

A Di Marco, A M Casazza, R Gambetta, R Supino, F Zunino.   

Abstract

The effects of 4'-epi-daunorubicin, 4'-epi-adriamycin, and the corresponding beta anomers on the in vitro activity of Escherichia coli DNA polymerase I and RNA polymerase were determined and compared with the effects of the parent compounds. The observed effects parallel the cytotoxic activities, assayed by inhibition of mouse embryo fibroblast proliferation, and the inhibitory activities on DNA synthesis in cultured cells. The data indicate that the inverted configuration at position 1 of the amino sugar results in a markedly reduced biological activity. This conclusion is also substantiated by the data obtained with the beta anomer of adriamycin. A preliminary investigation on the binding properties of these derivatives suggests that the inverted configuration at C-1' produces a significant decrease in the binding to DNA. In contrast, epimerization at position 4' did not produce any significant change in activity. The relationship between biological and biochemical activity and DNA binding properties of the tested compounds are discussed with particularly reference to antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773533

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Anthracyclines--modern tumour-inhibiting agents.

Authors:  D G Strauss
Journal:  Folia Microbiol (Praha)       Date:  1978       Impact factor: 2.099

Review 2.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

3.  Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.

Authors:  J Cummings; R Milroy; S W Banham; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 5.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

6.  Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.

Authors:  O Y Hu; S P Chang; J M Jame; K Y Chen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety.

Authors:  A Bargiotti; A M Casazza; G Cassinelli; A Di Marco; S Penco; G Pratesi; R Supino; A Zaccara; F Zunino; F Arcamone
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 8.  The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.

Authors:  A Goldin; J M Venditti; R Geran
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.